🚀 VC round data is live in beta, check it out!
Onconic Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Onconic Therapeutics and similar public comparables like Zentiva, Ironwood Pharmaceuticals, Abclon, Gyre Therapeutics and more.
Onconic Therapeutics Overview
About Onconic Therapeutics
Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201.
Founded
2020
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$692M
Onconic Therapeutics Financials
Onconic Therapeutics reported last fiscal year revenue of $36M and EBITDA of $10M.
In the same fiscal year, Onconic Therapeutics generated $36M in gross profit, $10M in EBITDA, and $11M in net income.
Revenue (LTM)
Onconic Therapeutics P&L
In the most recent fiscal year, Onconic Therapeutics reported revenue of $36M and EBITDA of $10M.
Onconic Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $36M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $36M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | $10M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 24% | XXX | XXX | XXX |
| Net Profit | — | XXX | $11M | XXX | XXX | XXX |
| Net Margin | — | XXX | 30% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Onconic Therapeutics Stock Performance
Onconic Therapeutics has current market cap of $728M, and enterprise value of $692M.
Market Cap Evolution
Onconic Therapeutics' stock price is $16.37.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $692M | $728M | 0.0% | XXX | XXX | XXX | $0.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOnconic Therapeutics Valuation Multiples
Onconic Therapeutics trades at 19.0x EV/Revenue multiple, and 71.1x EV/EBITDA.
EV / Revenue (LTM)
Onconic Therapeutics Financial Valuation Multiples
As of April 19, 2026, Onconic Therapeutics has market cap of $728M and EV of $692M.
Equity research analysts estimate Onconic Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Onconic Therapeutics has a P/E ratio of 67.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $728M | XXX | $728M | XXX | XXX | XXX |
| EV (current) | $692M | XXX | $692M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 19.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 71.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 80.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 19.0x | XXX | XXX | XXX |
| P/E | — | XXX | 67.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 91.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Onconic Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Onconic Therapeutics Margins & Growth Rates
Onconic Therapeutics' revenue in the last fiscal year grew by 260%.
Onconic Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 260% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (262%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 48% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Onconic Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Onconic Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| Ironwood Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Abclon | XXX | XXX | XXX | XXX | XXX | XXX |
| Gyre Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Astria Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Onconic Therapeutics M&A Activity
Onconic Therapeutics acquired XXX companies to date.
Last acquisition by Onconic Therapeutics was on XXXXXXXX, XXXXX. Onconic Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Onconic Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOnconic Therapeutics Investment Activity
Onconic Therapeutics invested in XXX companies to date.
Onconic Therapeutics made its latest investment on XXXXXXXX, XXXXX. Onconic Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Onconic Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Onconic Therapeutics
| When was Onconic Therapeutics founded? | Onconic Therapeutics was founded in 2020. |
| Where is Onconic Therapeutics headquartered? | Onconic Therapeutics is headquartered in South Korea. |
| Is Onconic Therapeutics publicly listed? | Yes, Onconic Therapeutics is a public company listed on Korea Exchange. |
| What is the stock symbol of Onconic Therapeutics? | Onconic Therapeutics trades under 476060 ticker. |
| When did Onconic Therapeutics go public? | Onconic Therapeutics went public in 2024. |
| Who are competitors of Onconic Therapeutics? | Onconic Therapeutics main competitors are Zentiva, Ironwood Pharmaceuticals, Abclon, Gyre Therapeutics. |
| What is the current market cap of Onconic Therapeutics? | Onconic Therapeutics' current market cap is $728M. |
| What is the current revenue of Onconic Therapeutics? | Onconic Therapeutics' last fiscal year revenue is $36M. |
| What is the current EV/Revenue multiple of Onconic Therapeutics? | Current revenue multiple of Onconic Therapeutics is 19.0x. |
| Is Onconic Therapeutics profitable? | No, Onconic Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.